TY - JOUR
T1 - Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
AU - Ubals, Maria
AU - Bosch-Nicolau, Pau
AU - Sánchez-Montalvá, Adrián
AU - Salvador, Fernando
AU - Aparicio-Español, Gloria
AU - Sulleiro Igual, Elena
AU - Silgado, Aroa
AU - Soriano-Arandes, Antoni
AU - Espiau, María
AU - Ferrer, Berta
AU - Pou, Diana
AU - Treviño Maruri, Begoña
AU - Molina Romero, Israel
AU - García-Patos Briones, Vicente
PY - 2021
Y1 - 2021
N2 - There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
AB - There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
KW - Cutaneous leishmaniasis
KW - Systemic therapy
KW - Liposomal amphotericin B
KW - Complex cutaneous leishmaniasis
KW - Leishmania
U2 - 10.3390/pathogens10101253
DO - 10.3390/pathogens10101253
M3 - Article
C2 - 34684202
SN - 2076-0817
VL - 10
JO - Pathogens
JF - Pathogens
IS - 10
ER -